Lactiplantibacillus plantarum P101 Modulates Hepatic Lipid Accumulation via AMPK Signaling in AFLD

Study Background and Research Question

Alcoholic liver disease (ALD) remains a major global health challenge, with alcoholic fatty liver disease (AFLD) as its earliest and most prevalent manifestation—affecting over 90% of individuals with chronic alcohol consumption and contributing to millions of deaths worldwide. AFLD is characterized by excessive triglyceride (TG) accumulation in the liver, resulting from impaired fatty acid oxidation and increased lipogenesis. Given the reversible nature of AFLD, early interventions are crucial for preventing progression to fibrosis and cirrhosis (reference study). Probiotic supplementation, particularly with Lactobacillus species, has emerged as a promising strategy for mitigating metabolic disorders, including those induced by alcohol. However, the precise mechanisms linking probiotic action to hepatic lipid metabolism and the role of key molecular pathways—such as AMPK (5′-adenosine monophosphate-activated protein kinase)—require further clarification. The present study investigates whether Lactiplantibacillus plantarum P101 (LP.P101) can alleviate alcohol-induced hepatic lipid accumulation and explores the underlying mechanisms, including the contribution of gut microbiota and metabolites.

Key Innovation from the Reference Study

The core innovation of this study lies in its integrative approach: it not only establishes the lipid-lowering effect of LP.P101 in an alcohol-induced mouse model but also demonstrates that this effect is mediated by activation of the AMPK signaling pathway. Crucially, the study incorporates targeted inhibition using Dorsomorphin, a well-characterized AMPK inhibitor, to validate the centrality of AMPK in this process. The authors further employ gut microbiota profiling and serum metabolomics, offering a systems-level perspective on how probiotic-driven metabolic changes may be orchestrated through gut-liver axis communication.

Methods and Experimental Design Insights

To model AFLD, mice were subjected to a short-term (10-day) ethanol-feeding protocol with a single binge episode, a strategy known to reliably induce hepatic steatosis. LP.P101 was administered daily via gavage at a concentration of 10⁸ CFU/mL. The experiment included the following groups: normal control, alcohol-fed, alcohol plus LP.P101, and alcohol plus LP.P101 with AMPK inhibition (via Dorsomorphin). Biochemical assays measured serum and hepatic markers (e.g., ALT, TG), while liver histology assessed lipid droplet accumulation. AMPK activation was quantified through phosphorylation status (Thr172 on AMPKα), and expression of downstream lipid metabolism genes was evaluated. The study also conducted 16S rRNA gene sequencing on fecal samples to characterize gut microbiota shifts, and untargeted metabolomics was performed on serum samples to identify systemic metabolic alterations.

Protocol Parameters

• Alcoholic liver disease induction: 10-day ethanol feeding plus single binge administration in mice.
• Probiotic intervention: LP.P101 at 10⁸ CFU/mL by daily oral gavage.
• AMPK inhibition: Dorsomorphin administered to validate pathway specificity (see product data for dosing and solubility guidelines).
• Biochemical and histological endpoints: Serum ALT, hepatic TG, histology for lipid droplets, AMPK phosphorylation, gene expression profiling.
• Microbiota and metabolomics profiling: 16S rRNA gene sequencing for compositional analysis; untargeted metabolomics on serum.

Core Findings and Why They Matter

The study's results demonstrate that LP.P101 supplementation significantly reduced hepatic lipid droplets and improved serum biochemical markers in alcohol-fed mice. Mechanistically, LP.P101 restored AMPK activation (as indicated by increased phosphorylation at Thr172) and modulated the expression of lipid metabolism genes—downregulating SREBP1c (lipogenesis) and upregulating PPARα (fatty acid oxidation). Importantly, when AMPK activity was pharmacologically inhibited by Dorsomorphin, the beneficial effects of LP.P101 on lipid accumulation and gene expression were abolished, underscoring the centrality of the AMPK pathway (reference study). On the gut microbiota level, LP.P101 reduced the Firmicutes/Bacteroidetes ratio—an alteration often linked to metabolic improvement. The abundance of Parabacteroides merdae was inversely correlated with hepatic lipid levels, while unclassified Negativibacillus was negatively associated with AMPK activation. Serum metabolomics revealed that stercobilinogen, a potential biomarker, was positively correlated with AMPK activation and negatively with lipid accumulation, suggesting a metabolic axis linking gut-derived metabolites with hepatic signaling. These findings provide compelling evidence that targeted activation of AMPK by probiotics can mediate both hepatic and systemic metabolic improvements in AFLD, with the gut microbiota and circulating metabolites serving as key modulators.

Comparison with Existing Internal Articles

Recent internal resources, such as "Dorsomorphin 2HCl: AMPK Inhibitor Workflows in Metabolic Research" and "Precision AMPK Inhibitor Workflows in Metabolic Research", detail the utility of Dorsomorphin 2HCl as a highly specific tool for dissecting AMPK-mediated metabolic pathways. These guides emphasize the importance of pathway-selective inhibition in preclinical models for reproducible and interpretable results, echoing the reference study's strategy of using Dorsomorphin to establish causality in AMPK-dependent outcomes. The internal article "L. plantarum P101 Attenuates Alcoholic Fatty Liver via AMPK Pathway" provides further context on the interplay between probiotics, hepatic metabolism, and signaling, reinforcing the mechanistic conclusions drawn in the present work. Collectively, these resources underscore the translational value of AMPK pathway modulation—whether by genetic, pharmacological, or microbial means—in metabolic disease research.

Limitations and Transferability

While the study robustly demonstrates the AMPK-dependent effect of LP.P101 in a short-term mouse model of AFLD, several limitations warrant consideration. First, translation to chronic or advanced ALD stages remains to be validated. The experimental timeframe and dosage may not fully recapitulate longer-term human exposure or dietary variability. Second, the specific molecular interactions between probiotic metabolites and hepatic AMPK activation require further elucidation; the identified biomarkers, such as stercobilinogen, are correlative and their causal roles remain to be established. Third, while Dorsomorphin is a widely used AMPK inhibitor, its off-target effects (such as BMP signaling inhibition) should be considered when interpreting results, though the study's design is consistent with established workflow recommendations. Despite these limitations, the integrated approach adopted here provides a strong framework for future translational research in both animal models and, potentially, clinical settings. The reliance on well-characterized pharmacological tools and multi-omics readouts enhances the study's reproducibility and generalizability within preclinical AFLD research.

Research Support Resources

Researchers aiming to dissect the role of AMPK in hepatic lipid metabolism or to replicate similar probiotic intervention workflows can utilize pathway-specific inhibitors such as Dorsomorphin 2HCl (SKU B1372). As detailed in the product dossier, Dorsomorphin 2HCl enables selective inhibition of AMPK and BMP signaling pathways, supporting precise mechanistic validation in metabolic, osteogenic, and iron homeostasis studies. For optimized application, follow manufacturer recommendations regarding solubility, dosing, and storage. These resources, alongside current experimental protocols, provide a robust foundation for advancing research into the gut-liver axis and metabolic disease mechanisms.